Seek Returns

BNTX vs. SMMT: BioNTech vs. Summit Therapeutics Stock Comparison

How do BioNTech (BNTX) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BioNTech (BNTX) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Summit Therapeutics (SMMT) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for BioNTech (BNTX) and Summit Therapeutics (SMMT)
Profile ItemBNTXSMMT
NameBioNTech SE American Depositary ShareSummit Therapeutics Inc.
Country/RegionGermanyUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization21.70 billion USD13.06 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateOctober 10, 2019March 5, 2015
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

BNTX
SMMT
GSPC
Loading price history…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for BioNTech (BNTX) and Summit Therapeutics (SMMT). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for BioNTech (BNTX) and Summit Therapeutics (SMMT). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BioNTech (BNTX) and Summit Therapeutics (SMMT)
MetricBNTXSMMT
Total Return (1Y)-14.78%-2.48%
Total Return (3Y, Annualized)-3.99%116.18%
Total Return (5Y, Annualized)-17.02%26.89%

Risk Profile

Drawdown History

BNTX
SMMT
GSPC
Loading price history…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for BioNTech (BNTX) and Summit Therapeutics (SMMT). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. BioNTech (BNTX) has a non-negative beta of 1.30.

Risk profile metrics for BioNTech (BNTX) and Summit Therapeutics (SMMT)
MetricBNTXSMMT
Volatility (1Y, Annualized)47.44%75.06%
Beta (5Y)1.30-1.51
Max Drawdown (5Y)-78.10%-87.64%
Avg. Volume (3M)1.21M6.19M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BNTX and SMMT are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BioNTech (BNTX) and Summit Therapeutics (SMMT)
MetricBNTXSMMT
Sharpe Ratio (1Y)-0.40-0.09
Sortino Ratio (1Y)-0.59-0.13

Profitability

ROE (TTM)

Both BioNTech (BNTX) at -8.14% and Summit Therapeutics (SMMT) at -220.01% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.14%

Max
109.18%
Q3
6.23%
BNTX
-8.14%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

-220.01%

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
SMMT
-220.01%
Loading chart…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Summit Therapeutics (SMMT) reports 0.00%, ranking against industry peers normally.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-60.87%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BNTX
-60.87%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
SMMT
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BioNTech (BNTX) at 30.28% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.28%

Max
83.12%
BNTX
30.28%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
SMMT
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BioNTech (BNTX) and Summit Therapeutics (SMMT)
MetricBNTXSMMT
ROE (TTM)-8.14%-220.01%
ROA (TTM)-4.04%-111.99%
Net Margin (TTM)-60.87%0.00%
Operating Margin (TTM)30.28%0.00%
Gross Margin (TTM)76.73%0.00%

Growth

Revenue Growth

Only one side can be read here: BioNTech (BNTX) reports revenue growth of 4.32%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Loading chart…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither BioNTech (BNTX) nor Summit Therapeutics (SMMT) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for BioNTech (BNTX) and Summit Therapeutics (SMMT)
MetricBNTXSMMT
Revenue Growth (YoY)4.32%--
Revenue Growth (3Y CAGR)-45.06%--
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both BioNTech (BNTX) at 8.55 and Summit Therapeutics (SMMT) at 5.99 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.55

Max
25.13
Q3
12.13
BNTX
8.55
Median
5.52
Q1
2.47
Min
0.10

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.99

Max
25.13
Q3
12.13
SMMT
5.99
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

BioNTech (BNTX) at 0.02 keeps leverage in the lower industry quartile, while Summit Therapeutics (SMMT) at 0.04 runs a more typical debt-to-equity mix.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
BNTX
0.02
Min
0.00

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.04

Max
1.42
Q3
0.65
Median
0.15
SMMT
0.04
Q1
0.02
Min
0.00
Loading chart…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for BioNTech (BNTX) and Summit Therapeutics (SMMT)
MetricBNTXSMMT
Current Ratio (MRQ)8.555.99
Debt / Equity (MRQ)0.020.04
Net Debt / EBITDA----

Dividends

Dividend Yield (TTM)

Neither BioNTech (BNTX) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BNTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BioNTech (BNTX) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BNTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BioNTech (BNTX) and Summit Therapeutics (SMMT)
MetricBNTXSMMT
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither BioNTech (BNTX) nor Summit Therapeutics (SMMT) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BNTX
--

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
SMMT
--
Loading chart…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

A sales-based read is only available for BioNTech (BNTX), whose P/S ratio of 8.96 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.96

Max
58.18
Q3
25.77
BNTX
8.96
Median
7.30
Q1
3.01
Min
0.01

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
SMMT
--
Loading chart…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT): SMMT does not report P/S ratio, so it has no value marker; BNTX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile relative to book while Summit Therapeutics (SMMT) at 23.13 prices above its industry range — a wide valuation gap against assets.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.09

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BNTX
1.09
Min
-5.59

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.13

SMMT
23.13
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
BioNTech (BNTX) vs. Summit Therapeutics (SMMT): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BioNTech (BNTX) and Summit Therapeutics (SMMT)
MetricBNTXSMMT
P/E Ratio (TTM)----
P/S Ratio (TTM)8.96--
P/B Ratio (MRQ)1.0923.13
Free Cash Flow Yield (TTM)-7.34%-1.64%